The Black Hole: CAR T Cell Therapy in AML
Despite exhaustive studies, researchers have made little progress in the field of adoptive cellular therapies for relapsed/refractory acute myeloid leukemia (AML), unlike the notable uptake for B cell malignancies. Various single antigen-targeting chimeric antigen receptor (CAR) T cell Phase I trial...
Main Authors: | Erden Atilla, Karim Benabdellah |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/10/2713 |
Similar Items
-
A Panorama of Immune Fighters Armored with CARs in Acute Myeloid Leukemia
by: Ilias Christodoulou, et al.
Published: (2023-06-01) -
Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
by: Utkarsh H. Acharya, et al.
Published: (2020-12-01) -
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
by: Faroogh Marofi, et al.
Published: (2021-08-01) -
Chimeric antigen receptor‐engineered adoptive cell therapy for AML: Current status and future perspectives
by: Yue Huang, et al.
Published: (2022-06-01) -
Chimeric Antigen Receptor T Cell Therapy in Acute Myeloid Leukemia: Trials and Tribulations
by: Swati Garg, et al.
Published: (2023-11-01)